Study guide
2.3 Autoimmune & Rheumatologic Disease Principles
USMLE Step 2 CK Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Human Development & Well-Patient Care
1.1 Infant, Child & Adolescent Development & Growth 1.2 Adult Development, Aging & Geriatric Assessment 1.3 Preventive Health, Immunization & Well-Patient Screening
2 Chapter 2: Immune System & Immunologic Disorders
2.1 Primary & Secondary Immunodeficiencies 2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis 2.3 Autoimmune & Rheumatologic Disease Principles
3 Chapter 3: Blood & Lymphoreticular System
3.1 Anemias: Microcytic, Normocytic & Macrocytic Etiologies 3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology 3.3 Hematologic Malignancies & Lymphoproliferative Disorders
4 Chapter 4: Behavioral Health & Psychiatric Disorders
4.1 Mood Disorders: Major Depression & Bipolar Spectrum 4.2 Anxiety, Trauma-Related & Somatic Symptom Disorders 4.3 Psychotic Disorders & Schizophrenia Spectrum 4.4 Substance Use Disorders & Psychopharmacology
5 Chapter 5: Nervous System & Special Senses
5.1 Cerebrovascular Disease, Stroke & Transients 5.2 Seizures, Epilepsy & Altered Mental Status 5.3 Movement Disorders, Dementia & Peripheral Neuropathies 5.4 Special Senses: Ophthalmologic & Otolaryngologic Emergencies
6 Chapter 6: Musculoskeletal System & Dermatology
6.1 Fractures, Dislocations & Orthopedic Trauma 6.2 Inflammatory Arthropathies & Crystal-Induced Diseases 6.3 Inflammatory & Infectious Dermatoses 6.4 Cutaneous Malignancies & Blistering Disorders
7 Chapter 7: Cardiovascular System
7.1 Coronary Artery Disease & Acute Coronary Syndromes 7.2 Heart Failure, Cardiomyopathies & Valvular Disease 7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation 7.4 Vascular Emergencies: Aortic Aneurysms & Peripheral Arterial Disease
8 Chapter 8: Respiratory System
8.1 Obstructive Airway Diseases: Asthma & COPD 8.2 Infectious Pneumonias & Pleural Effusions 8.3 Pulmonary Vascular Disease & Thromboembolism 8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases
9 Chapter 9: Gastrointestinal System
9.1 Esophageal, Gastric & Peptic Ulcer Disorders 9.2 Inflammatory Bowel Disease & Colorectal Neoplasms 9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension 9.4 Biliary Tract Diseases & Pancreatitis
10 Chapter 10: Renal, Urinary & Reproductive Systems
10.1 Acute Kidney Injury & Chronic Kidney Disease 10.2 Glomerular & Tubulointerstitial Diseases 10.3 Nephrolithiasis, Urinary Tract Infections & Prostate Pathology 10.4 Fluid, Electrolyte & Acid-Base Disorders 10.5 Female Reproductive Disorders & Gynecology 10.6 Breast Pathology & Clinical Breast Disease
11 Chapter 11: Pregnancy, Childbirth & Puerperium
11.1 Normal Prenatal Care & Maternal-Fetal Physiology 11.2 Medical & Obstetric Complications of Pregnancy 11.3 Labor, Delivery & Postpartum Management
12 Chapter 12: Endocrine System
12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies 12.2 Thyroid & Parathyroid Disorders 12.3 Adrenal & Pituitary Axis Pathology
13 Chapter 13: Multisystem Processes & Critical Care
13.1 Shock States, Sepsis & Systemic Inflammatory Response 13.2 Environmental Emergencies, Toxicology & Overdose 13.3 Infectious Disease Principles & Systemic Pathogens
14 Chapter 14: Biostatistics, Epidemiology & Literature Interpretation
14.1 Study Designs, Bias & Validity 14.2 Diagnostic Testing: Sensitivity, Specificity, PPV & NPV 14.3 Statistical Significance, Risk Measures & Evidence-Based Medicine
15 Chapter 15: Social Sciences, Ethics & Systems-Based Practice
15.1 Medical Ethics, Informed Consent & Patient Autonomy 15.2 Legal Issues, Confidentiality & Surrogate Decision Making 15.3 Patient Safety, Quality Improvement & Medical Error Analysis 15.4 Health Care Delivery Systems, Interprofessional Care & Transitions
2.3 Autoimmune & Rheumatologic Disease Principles
Key Takeaways Explain This Topic AI
Antinuclear antibody (ANA) has high sensitivity (>95%) as a screening test for SLE, while anti-dsDNA (titers correlate with lupus nephritis activity) and anti-Smith antibodies provide high specificity (>98%) for confirming diagnosis.
Rheumatoid Factor (RF) occurs in 70–80% of RA cases but lacks specificity; Anti-Cyclic Citrullinated Peptide (anti-CCP) antibodies show equivalent sensitivity with superior specificity (>95%) for RA and predict aggressive erosive disease.
Synovial fluid analysis differentiates joint effusions: inflammatory arthritis presents with WBC 2,000–50,000/mm³, whereas septic arthritis presents with WBC >50,000/mm³ (often >100,000/mm³) with >75–90% PMNs requiring urgent empiric IV antibiotics and drainage.
Granulomatosis with Polyangiitis (GPA/Wegener) is strongly associated with PR3-ANCA/c-ANCA (>90% sensitivity in active disease), causing necrotizing granulomas of the upper/lower respiratory tract and pauci-immune glomerulonephritis.
Anti-Ro/SSA and Anti-La/SSB antibodies cross the placenta in pregnant mothers with Sjögren syndrome or SLE, carrying a risk of neonatal lupus and congenital heart block; Systemic sclerosis subtypes are distinguished by anti-centromere (limited/CREST) versus anti-Scl-70 (diffuse) antibodies.
Last updated: July 2026
- Autoimmune & Rheumatologic Disease Principles
- Diagnostic Approach & Autoantibody Profiling
Autoimmune rheumatologic diseases result from a breakdown of immunological self-tolerance, leading to autoreactive B- and T-cell responses against host tissues. Clinical presentation spans multisystem involvement (Systemic Lupus Erythematosus, Systemic Sclerosis) to targeted organ inflammation (Rheumatoid Arthritis, ANCA-associated vasculitides). On USMLE Step 2 CK, diagnostic evaluation centers on matching specific clinical syndromes with high-yield autoantibody profiles , inflammatory marker patterns, and synovial fluid analysis .
High-Yield Rheumatologic Autoantibody Master Table
Autoantibody Target Antigen Associated Disease State Sensitivity / Specificity Clinical Utility & Diagnostic Significance
ANA (Antinuclear Antibody) Nuclear antigens Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Sjögren Sensitivity >95% (SLE), Specificity Low (~50%) Initial screening test for connective tissue disease; negative test strongly excludes SLE
Anti-dsDNA Double-stranded DNA Systemic Lupus Erythematosus (SLE) Sensitivity 60–70%, Specificity >98% Highly specific for SLE; titers correlate with disease activity and lupus nephritis risk
Anti-Smith (Anti-Sm) Core snRNP proteins Systemic Lupus Erythematosus (SLE) Sensitivity 20–30%, Specificity >98% Highly specific diagnostic marker for SLE; titers do NOT fluctuate with disease activity
Anti-CCP (Cyclic Citrullinated Peptide) Citrullinated proteins Rheumatoid Arthritis (RA) Sensitivity 70–80%, Specificity >95% Most specific diagnostic marker for RA; predicts erosive disease progression
Rheumatoid Factor (RF) Fc portion of human IgG Rheumatoid Arthritis, Sjögren, Hepatitis C Sensitivity 70–80%, Specificity 70% Screen for RA; positive in many non-rheumatologic conditions (endocarditis, HCV)
c-ANCA (PR3-ANCA) Proteinase 3 Granulomatosis with Polyangiitis (GPA / Wegener) Sensitivity >90% (active disease), Specificity >95% Associated with upper airway, pulmonary nodular, and pauci-immune glomerulonephritis
p-ANCA (MPO-ANCA) Myeloperoxidase Microscopic Polyangiitis (MPA), Eosinophilic GPA (EGPA) Sensitivity 60–80%, Specificity >90% Associated with pulmonary-renal syndrome without granulomas (MPA) or asthma/eosinophilia (EGPA)
Anti-Ro / SSA & Anti-La / SSB Ribonucleoprotein particles Sjögren Syndrome, Systemic Lupus Erythematosus Sensitivity 70–90% (Sjögren), Moderate (SLE) Associated with sicca symptoms; pregnant mothers risk transmitting neonatal congenital heart block
Anti-Centromere Centromeric proteins Limited Cutaneous Systemic Sclerosis (CREST) Sensitivity 60–80%, Specificity >95% Associated with Calcinosis, Raynaud, Esophageal dysmotility, Sclerodactyly, Telangiectasias
Anti-Scl-70 (Anti-Topoisomerase I) DNA Topoisomerase I Diffuse Cutaneous Systemic Sclerosis Sensitivity 30–40%, Specificity >98% Associated with rapid skin involvement and early progressive interstitial lung disease
Anti-Jo-1 (Anti-Histidyl tRNA Synthetase) tRNA Synthetase Polymyositis, Dermatomyositis Sensitivity 20–30%, Specificity >95% Associated with Antisynthetase syndrome (interstitial lung disease, mechanic's hands, fever)
Anti-U1 RNP U1 small nuclear RNP Mixed Connective Tissue Disease (MCTD) Sensitivity >95% for MCTD, Specificity High Required criterion for diagnosing MCTD (features of SLE, systemic sclerosis, polymyositis)
Synovial Fluid Analysis & Joint Disease Differentiation
When evaluating a patient with joint pain and effusion, arthrocentesis with synovial fluid analysis is the crucial mandatory diagnostic step to differentiate non-inflammatory, inflammatory, crystal-induced, and septic joint etiologies.
Synovial Fluid Interpretation Matrix
Fluid Category Appearance Clarity WBC Count (/mm³) PMNs (%) Glucose Ratio (Fluid:Blood) Common Clinical Diagnoses
- Normal Straw/Clear Transparent <200 <25% ~1.0 Healthy joint
- Non-Inflammatory Yellow Transparent 200 to 2,000 <25% >0.8 Osteoarthritis, Trauma, Charcot joint
Inflammatory Yellow to Opalescent Translucent 2,000 to 50,000 50% to 75% 0.5 to 0.8 Rheumatoid arthritis, SLE, Gout, Pseudogout, Reactive arthritis
Septic Turbid / Purulent Opaque >50,000 (often >100,000) >75% to 90% <0.5 Staphylococcus aureus , Neisseria gonorrhoeae , Streptococcal infection
Hemorrhagic Red / Bloody Opaque 200 to 2,000 (RBCs predominant) Variable ~1.0 ACL tear, Intra-articular fracture, Hemophilia, Anticoagulant overdose
- Diagnostic Evaluation Algorithm for Arthritis Patient Presenting with Joint Pain & Swelling
- ├─ Step 1: Physical Exam & History (Monoarticular vs Polyarticular; Inflammatory vs Non-inflammatory)
- │ ├─ Inflammatory: Morning stiffness >60 min, improves with activity, systemic symptoms
- │ └─ Non-inflammatory: Morning stiffness <30 min, worsens with weight-bearing
- │
- ├─ Step 2: Acute Monoarthritis → MANDATORY ARTHROCENTESIS
│ ├─ Synovial WBC >50,000/mm³ + PMNs >75% → SEPTIC ARTHRITIS (Empiric IV Vancomycin + Cefepime + Surgical Drainage)
- │ ├─ Polarized Microscopy: Needle-shaped, negatively birefringent crystals → GOUT (Monosodium urate)
- │ └─ Polarized Microscopy: Rhomboid, positively birefringent crystals → PSEUDOGOUT (Calcium pyrophosphate)
- │
- └─ Step 3: Polyarthritis (Multiple Joints Involved)
- ├─ Symmetrical Small Joint Involvement (MCPs, PIPs, Wrists; Sparing DIPs)
- │ └─ Order RF, Anti-CCP, ESR, CRP, Hand/Wrist Radiographs
- │ ├─ Anti-CCP (+) & RF (+) with marginal joint erosions → RHEUMATOID ARTHRITIS
- │ └─ Initiate Early Disease-Modifying Antirheumatic Drug (DMARD: Methotrexate)
- │
- └─ Multisystem Features (Malar rash, Photosensitivity, Serositis, Cytopenias)
- └─ Order Initial Screen: ANA (Antinuclear Antibody)
- ├─ If ANA Positive → Order Specific Panel: Anti-dsDNA, Anti-Smith, Complement C3/C4, Urinalysis
- └─ Anti-dsDNA (+), Anti-Sm (+), Low C3/C4 → SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
- Core Pharmacotherapy & Disease-Modifying Principles
- Conventional Synthetic DMARDs
Methotrexate : First-line disease-modifying therapy for Rheumatoid Arthritis. Acts via competitive inhibition of dihydrofolate reductase , impairing DNA synthesis. Requires co-administration of folic acid (1–5 mg/day) to prevent mucosal ulceration, cytopenias, and hepatotoxicity. Monitoring requires baseline chest radiograph (pulmonary fibrosis risk) and periodic complete blood counts and liver enzymes.
Hydroxychloroquine : Mild DMARD utilized in SLE and mild RA. Inhibits toll-like receptor signaling. Major adverse effect is retinal toxicity (maculopathy) , mandating baseline and annual ophthalmologic examination with visual field testing and optical coherence tomography (OCT).
Sulfasalazine : Useful in peripheral spondyloarthropathies and RA; metabolized by intestinal bacteria into sulfapyridine and 5-ASA. Side effects include leukopenia and reversible oligospermia.
Biologic DMARDs
TNF-Alpha Inhibitors (Infliximab, Adalimumab, Etanercept): Potent biologic agents for refractory RA, psoriatic arthritis, and ankylosing spondylitis. Mandatory pre-treatment screening includes Tuberculin skin test (PPD) or Interferon-Gamma Release Assay (IGRA) alongside Hepatitis B virus serologies due to severe risk of reactivation of latent tuberculosis and viral hepatitis.